LLY Eli Lilly and Company
Company Analysis
Latest News
Eli Lilly Downgraded to Reduce, HSBC Cites Smaller Obesity Market Outlook
HSBC downgraded Eli Lilly from Hold to Reduce. The bank slashed its price target from $1,070 to $850. Analysts estimate the total addressable obesity market...
Eli Lilly EBGLYSS Succeeds in Phase 3 Trial for Pediatric Eczema
Eli Lilly and Company reported positive topline results from its Phase 3 ADorable-1 trial for EBGLYSS (lebrikizumab-lbkz). The study evaluated pediatric...
Eli Lilly warns of impurities in compounded Zepbound, citing health risks
Eli Lilly issued a public warning regarding safety risks in compounded versions of tirzepatide. This active ingredient is used in the company’s Zepbound and...
Eli Lilly Commits $3B to China Supply Chain for Experimental Weight-Loss Pill
Eli Lilly and Company plans to invest $3 billion in China over the next decade. This capital will expand the company's supply chain and establish production...
Eli Lilly Obesity Franchise Set for 2027 Medicare Expansion Under New CMS Model
Eli Lilly and Company announced that Medicare Part D plans will begin covering its leading obesity treatments on January 1, 2027. The expansion follows new...
Eli Lilly Pledges $500 Million to South Korea to Anchor New Biotech Incubation Hub
Eli Lilly and Company committed $500 million to South Korea’s pharmaceutical and biotechnology sector over the next five years. The company formalized this...
Eli Lilly Captures 60% of New GLP-1 Prescriptions as Morgan Stanley Reaffirms Overweight Rating
Morgan Stanley reiterated its Overweight rating for Eli Lilly and Company. The investment bank maintained a price target of $1,313 per share. Prescriptions...
🔴 LLY is trading 3.4% down today on geopolitical tensions and a broader market selloff
LLY is trading at $969.90 (-3.4%) as geopolitical tensions and profit-taking drive a sharp decline across major indices. - Major indices are under pressure...
Eli Lilly Launches Employer Connect to Bridge Obesity Drug Coverage Gap for Millions of Workers
Eli Lilly and Company launched its Employer Connect platform on March 5, 2026. This initiative increases employee access to obesity medications through...
Eli Lilly Finalizes Acquisition of Ventyx Biosciences
Eli Lilly and Company finalized its acquisition of Ventyx Biosciences on March 4, 2026. Ventyx now operates as a wholly owned subsidiary. The transaction...
Eli Lilly's Pipeline Strength and Diversification Strategy Reassessed
Eli Lilly updated its pipeline in late February 2026. The company reported Phase 3 data for orforglipron, an oral GLP-1 candidate. The Zepbound KwikPen...
🔴 LLY is trading 3.14% down
LLY is trading at $1018.96, down 3.14%.
🔴 LLY is trading 3% down today as it underperforms a broader market recovery
LLY is trading at $1020.29 (-3.01%) as the stock lags behind a broader market recovery. - Major indices are trending higher, with the S&P 500 up 0.29% and the...
Eli Lilly Shares Fall as Novo Nordisk Commits $500M to Wegovy Pill Expansion
Eli Lilly shares fell approximately 2% on March 2, 2026. The decline followed reports that rival Novo Nordisk is investing over $500 million to expand...
Eli Lilly Oral GLP-1 Beats Novo Nordisk Rival in Phase 3 Trial Amid Tolerability Concerns
Eli Lilly's oral GLP-1 candidate, orforglipron, demonstrated superior efficacy compared to Novo Nordisk's Rybelsus in a head-to-head Phase 3 trial for adults...
Eli Lilly Wins Major Biotech Licensing Dispute, Avoiding $278M Payout
Eli Lilly won a licensing dispute regarding an alleged breach of agreement. The company avoided a $278 million payout. The verdict removes financial...
Eli Lilly Widens Lead in Obesity Market as Wall Street Bets on Oral GLP-1 Pipeline
JPMorgan, Deutsche Bank, and RBC Capital reiterated their confidence in Eli Lilly’s leadership within the expanding obesity treatment market. The investment...
Lilly’s Oral Orforglipron Outperforms Novo’s Semaglutide in Landmark Head-to-Head Trial
Eli Lilly’s experimental once-daily oral drug, orforglipron, demonstrated superior efficacy over Novo Nordisk’s oral semaglutide in a Phase 3 head-to-head...
Eli Lilly Shares Slide as Novo Nordisk Signals 50% Price Cuts for GLP-1 Rivals
Eli Lilly (LLY) shares declined in premarket trading following a pricing announcement from primary rival Novo Nordisk. Novo Nordisk plans to reduce prices for...
Eli Lilly Stock Jumps on Zepbound KwikPen Approval as Rival Novo Nordisk Tumbles 16%
Eli Lilly and Company received U.S. FDA approval for the Zepbound KwikPen, a multi-dose injector for its weight-loss medication. This new device delivers four...